TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients

A Phase II study evaluating the safety and efficacy of TGRX-678 in Chronic Myelogenous Leukemia (CML) patients in Accelerated phase (AP) and are relapsed or refractory from third-generation Tyrosine Kinase Inhibitor (TKI) treatment

Trial Details

NCT ID
NCT06453902
Phase
PHASE2
Sponsor
Shenzhen TargetRx Co., Ltd.
Status
RECRUITING
Cancer Type
Chronic Myeloid (CML) Leukemia
Interventions
  • TGRX-678
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Willing to consent
  • 18 years of age or above at time of screening; both sexes eligible
  • Relapsed or refactory from 3rd-generation Tyrosine kinase inhibitor (TKI) treatment
  • For patients without T315I mutation, the patients must received 1st, 2nd and 3rd generation TKI

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Chronic Myeloid (CML) Leukemia Trials on Trialify →